CNS Pharmaceuticals Inc expected to post a loss of $9.66 a share - Earnings Preview

CNS Pharmaceuticals

28/03/2025 11:02

CNS Pharmaceuticals Inc CNSP.OQ CNSP.O is expected to report resultson March 31 (estimated) for the period ending December 31 2024

​LSEG's mean analyst estimate for CNS Pharmaceuticals Inc is for a loss of $9.66 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for CNS Pharmaceuticals Inc is $200.00​, above​ its last closing price of $1.32. ​​​

This summary was machine generated March 28 at 11:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)